Friday 16 May, 2025 03:51 PM
Site map | Locate Us | Login
   Dhanuka Agritech spurts after Q4 PAT climbs 28% YoY to Rs 76 cr    BHEL gains as Q4 PAT rises 3% YoY to Rs 504 crore    SKF India soars after recording nearly 86% sequential rise in Q4 PAT    Paradeep Phosphates Ltd leads losers in 'A' group    Neuland Labs drops after Q4 PAT slumps 59% YoY to Rs 28 cr    IRCON International spurts on bagging Rs 52-cr railway order    DDev Plastiks Industries Ltd leads losers in 'B' group    India Ratings revises rating outlook of Bajaj Healthcare to 'stable'; affirms rating at 'A-    NOCIL slumps after Q4 PAT slips 50% YoY to Rs 21 crore    Volumes jump at JSW Infrastructure Ltd counter    Matrimony.com Q4 PAT slides 30 YoY to Rs 8 cr; recommends final dividend of Rs 5/ share    Eureka Forbes spurts after robust Q4 numbers    Information Technology stocks slide    Crisil Ratings reaffirms ratings of VST Industries at 'AA+' with 'stable' outlook    Balrampur Chini Q4 PAT rises 13% YoY to Rs 229 crore 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Biocon's subsidiary get US FDA nod for anticoagulant medication Rivaroxaban
16-May-25   09:38 Hrs IST

Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and pulmonary embolism, to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

The approval will further strengthen Biocon's portfolio of vertically integrated drug products,' the company said in a statement.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets.

The company's consolidated net profit surged 154.24% to Rs 344.50 crore in Q4 FY25, compared with Rs 135.50 crore in Q4 FY24. Revenue from operations increased 12.76% YoY to Rs 4,417 crore during the period under review.

The scrip rose 0.89% to currently trade at Rs 341.55 on the BSE.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC Hit Count : 40889568
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited